Pre-transplant blinatumomab improves outcomes in B-cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation

Acute lymphoblastic leukemia (ALL) is the most common cancer in children.1 It carries an excellent prognosis with 5-year overall survival (OS) rates of up to 90%.2 Pediatric-inspired intensive regimens are also used to treat adolescents and young adults age 15 –39 (AYA), with an estimated 3-year OS in this group of 73%.3

Source: Biology of Blood and Marrow Transplantation - March 8, 2024 Category: Hematology Authors: Ayman Sayyed, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H. Lipton, Fotios V. Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic Source Type: research